

RowLabel	52427085060	52427089060
NDC11	52427085060	52427089060
Trade Name	Gralise Tablets, 750mg	Gralise Tablets, 900mg
Chemical Name	gabapentin	gabapentin
Product introduction date	4/25/2023	4/25/2023
Wholesale Acquisition Cost (WAC) per package	\$957.72	\$957.72
Wholesale Acquisition Cost (WAC) per treatment course	\$957.72	\$957.72
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	<p>Gralise is promoted by our commercial field team to healthcare professionals to educate them on our product. We use various means of promotion including in-office visits, virtual meetings, and non-personal digital marketing. A website www.gralise.com provides further information about Gralise. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.</p>	<p>Gralise is promoted by our commercial field team to healthcare professionals to educate them on our product. We use various means of promotion including in-office visits, virtual meetings, and non-personal digital marketing. A website www.gralise.com provides further information about Gralise. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers. Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Gralise. These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.</p>
Estimated volume of patients who may be prescribed the drug	137	273
Granted breakthrough therapy designation or priority review by the FDA?	No	No
Date of acquisition (if acquired)		
Price of acquisition (if acquired)		